Virginiamycin M1 (from Streptomyces virginiae) ~95% (by TLC), Sigma-Aldrich®

Supplier: Merck


M-Clarity™ quality level = MQ200

V2753-10MG V2753-5MG
SIALV2753-10MGEA 642 EUR
SIALV2753-10MG SIALV2753-5MG
Virginiamycin M1 (from Streptomyces virginiae) ~95% (by TLC), Sigma-Aldrich®
Virginiamycin M1

The antibiotic virginiamycin is produced by S. virginiae and is a member of the virginiamycin family.


Each member is produced as a mixture of two structurally different compounds that exhibit synergistic antibacterial activity. There are two groups: virginiamycin M1 (VM1) and virginiamycin S (VS). VM1 is a polyunsaturated macrocyclic petolide. VM1 and VS are both used to inhibit protein synthesis since they are bacteriostatic. When used in combination they are more effective. Virginiamycin is used as a performance promoter in animal husbandry. They are chemically modified to make therapeutic drugs such as quinupristin and dalfopristin.


Virginiamycin M1 inhibits bacterial protein synthesis at the level of aminoacyl-tRNA binding and peptide bond formation. It inactivates the 50S ribosome. S. virginiae inactivates VM1 by reducing its 16-carbonyl group, forming 16R-dihydroVM1. VM1 reductase participates solely in VM1 inactivation in vivo.

Formula: C₂₈H₃₅N₃O₇
Storage Temperature: Refrigerator
CAS Number: 21411-53-0
EINECS: 244-376-6

Order Now

Specification Test Results

C% anhydrous (Elemental analysis) 63.00 - 64.50%
N% anhydrous (Elemental analysis) 7.70 - 8.70%
Purity (TLC) ≥93.00%


Learn more

About VWR

Avantor is a vertically integrated, global supplier of discovery-to-delivery solutions for...

Learn more About VWR